Felzartamab in Late Antibody-Mediated Rejection

NCT05021484 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

22

Enrollment

OTHER

Sponsor class

Conditions

Antibody-mediated Rejection

Interventions

DRUG: Felzartamab
DRUG: Placebo

Sponsor

Farsad Eskandary

Collaborators

[object Object]
[object Object]
[object Object]